<DOC>
	<DOCNO>NCT02382406</DOCNO>
	<brief_summary>This phase I/II study previously untreated subject advance NSCLC . The study take place two phase . First , cohort twelve participant enrol phase I part treat carboplatin , nab-paclitaxel pembrolizumab . A cohort twelve subject evaluate safety tolerability 2 cycle therapy . All subject receive either nab-paclitaxel pembrolizumab evaluable . If 33 % subject less unacceptable toxicity first cohort subsequent cohort ( necessary ) , study proceed Phase II part . If 33 % unacceptable toxicity , 12 additional subject enrol second cohort , necessary . If unacceptable toxicity see 33 % Cohort 2 , study end due unacceptable toxicity drug combination . The phase II part study single arm study . All subject treat carboplatin , nab-paclitaxel , pembrolizumab 21-day cycle 4 cycle . Mandatory pre-treatment tumor biopsy obtain prior initiate treatment subject ( adequate archive sample unavailable ) . Mandatory tumor biopsy obtain Phase II part study 4 cycle study treatment time progression , whichever come first . For subject without progression disease Cycle 4 , pembrolizumab continue every 3 week 2 year unacceptable toxicity .</brief_summary>
	<brief_title>Carboplatin/Nab-Paclitaxel Pembrolizumab NSCLC</brief_title>
	<detailed_description>OUTLINE : This multi-center study . INVESTIGATIONAL TREATMENT : Phase I , Cohort 1 Induction Therapy : - Carboplatin AUC 6 IV , Day 1 - Nab-paclitaxel 100 mg/m^2 IV , Days 1 , 8 , 15 - pembrolizumab 2 mg/kg IV , Day 1 - Cycle length : 21 day ; number cycle : 4 Phase I , Cohort 1 Maintenance Therapy : For subject confirm CR , PR , SD ( non-progression ) 4 cycle induction therapy , maintenance therapy pembrolizumab 2* mg/kg continue Day 1 21-day cycle . Treatment continue progression disease , unacceptable toxicity , maximum 2 year Cycle 1 , Day 1 ( C1D1 ) . Subjects complete 24 month treatment pembrolizumab may eligible one year additional study treatment progress stop study treatment provide continue meet inclusion criterion requirement . If unacceptable toxicity see Phase I , Cohort 1 , 12 additional participant enrol . Phase I , Cohort 2 Induction Therapy ( necessary ) : - Carboplatin AUC 6 IV , Day 1 - Nab-paclitaxel 100 mg/m^2 IV , Days 1 , 8 , 15 - pembrolizumab 2 mg/kg IV , Day 1 ( cycle 2-4 ) - Cycle length : 21 day ; Number cycle : 4 Phase I , Cohort 2 Maintenance Therapy : For subject confirm CR , PR , SD ( non-progression ) 4 cycle induction therapy , maintenance therapy pembrolizumab 2* mg/kg continue Day 1 21-day cycle . Treatment continue progression disease , unacceptable toxicity , maximum 2 year Cycle 2 , Day 1 ( C2D1 ) . Subjects complete 24 month treatment pembrolizumab may eligible one year additional study treatment progress stop study treatment provide continue meet inclusion criterion requirement . Phase II Induction Therapy : - Carboplatin AUC 6 IV , Day 1 - Nab-paclitaxel 100 mg/m^2 IV , Days 1 , 8 , 15 - pembrolizumab 200mg IV , Day 1 cycle - Cycle length : 21 day ; number cycle : 4 Phase II Maintenance Therapy : For subject confirm CR , PR , SD ( non-progression ) 4 cycle induction therapy , maintenance therapy pembrolizumab 200 mg continue Day 1 21-day cycle . Treatment continue progression disease , unacceptable toxicity , maximum 2 year Cycle 1 , Day 1 ( C1D1 ) . Subjects complete 24 month treatment pembrolizumab may eligible one year additional study treatment progress stop study treatment provide meet requirement . *As additional data ongoing trial becomes available , dose pembrolizumab may adjust .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Subjects must willing able provide write informed consent trial HIPAA authorization release personal health information . NOTE : HIPAA authorization may include informed consent obtain separately . Subjects must ≥ 18 year age . Individuals stage IIIB IV , unresectable nonsmall cell lung cancer ( NSCLC ) receive prior chemotherapy Stage IIIB IV disease , candidate curative surgery radiation therapy . ECOG performance status ( PS ) 01 Measurable disease RECIST v1.1 criterion Prior registration , subject must archival tissue available . For subject archival tissue , PDL1 test result use Dako 22C3 antibody , subject permit enroll without submit tissue . If patient prior test acceptable archival tissue available , subject must willing consent provide pretreatment biopsy PDL1 testing . Regardless PDL1 test status , archival tissue request research test available . Phase II subject must willing consent provide mandatory posttreatment core biopsy research clinical feasible . Women eligible participate nonchildbearing potential documentation negative pregnancy test ( serum urine βhCG ) within 3 day registration . Sexually active premenopausal woman childbearing potential must agree use adequate , highly effective contraceptive measure , start first dose study drug 120 day last dose last study drug . Effective birth control include ( ) intrauterine device ( IUD ) plus one barrier method ; ( b ) oral , implantable , injectable contraceptive plus one barrier method ; ( c ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) . Women childbearing potential surgically sterilize free menses ≥ 1 year . Male participant agree use adequate method contraception start first dose study drug 120 day last dose last study drug . Individuals presence symptomatic CNS metastasis require radiation treatment , surgery , ongoing use corticosteroid . Untreated brain metastasis causing symptom , neurologic deficit headache . Individuals previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose study drug neurologic symptom return baseline whole brain radiation stereotactic radiosurgery complete 4 week prior registration ) , evidence new enlarge brain metastasis , use steroid least 7 day prior study treatment . History solid organ stem cell transplant require immunosuppressive medication . Any prior adjuvant cytotoxic chemotherapy within 12 month registration . Subjects receive chemotherapy earlier stage disease 12 month prior study registration eligible trial . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Any radiotherapy within 2 week prior registration ( 4 week brain radiotherapy note ) . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . History invasive malignancy currently active and/or treat within 12 month registration . ( Notable exception include : basal cell carcinoma , squamous cell carcinoma skin , localized prostate cancer , situ carcinoma cervix breast , superficial bladder cancer [ nonmuscleinvasive ] ) . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Pulmonary condition sarcoidosis , silicosis , idiopathic pulmonary fibrosis , hypersensitivity pneumonitis . Has history pneumonitis require steroid current pneumonitis . Preexisting peripheral neuropathy ≥ Grade 2 CTCAE v 4.0 criterion . Known significant liver disease include viral , alcoholic , active hepatitis B C , and/or cirrhosis . Abnormal liver renal function define : bilirubin ≥ 1.5 mg/dL ; AST ALT ≥ 2.5 x ULN ; alkaline phosphatase &gt; 2.5 x ULN , upper limit bone metastasis present absence liver metastasis ; creatinine &gt; 1.5 mg/dL Abnormal baseline hematologic coagulation parameter define : absolute neutrophil count ( ANC ) &lt; 1.5 x 10^9/L ; hemoglobin &lt; 9.0 g/dL ; platelet &lt; 100 x 10^9/L ; International Normalized Ratio ( INR ) prothrombin time ( PT ) ≥ 1.5 x ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant ; Activated Partial Thromboplastin Time ( aPTT ) ≥ 1.5 x ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant Has receive live vaccine within 30 day prior first dose study drug . Known activate EGFR mutation ALK translocation Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose pembrolizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MK-3475</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Nab-paclitaxel</keyword>
</DOC>